Home › Funds › SUPERSTRING CAPITAL MANAGEMENT LP › CABA
SUPERSTRING CAPITAL MANAGEMENT LP position in CABA
CABALETTA BIO INC · Health Care
SUPERSTRING CAPITAL MANAGEMENT LP reported holding 1,278,652 shares of CABA (CABALETTA BIO INC) in its Q2 2026 13F filing — a position valued at US$3.5M, representing 2.20% of its reported portfolio and ranking #19 among its reported holdings. SUPERSTRING CAPITAL MANAGEMENT LP has disclosed CABA holdings in 10 of the last 10 reported quarters, going back to Q1 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How SUPERSTRING CAPITAL MANAGEMENT LP's CABA position evolved
SUPERSTRING CAPITAL MANAGEMENT LP first disclosed a stake in CABA in Q1 2024 at 290,797 shares (US$5.0M). Across 10 filings, SUPERSTRING CAPITAL MANAGEMENT LP increased the stake 5 time(s), trimmed it 4 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 1,278,652 shares valued at US$3.5M — an increase of 212,413 shares quarter over quarter.. Notable position changes include a 524% increase in Q4 2024 (shares fell 39% over the following quarter), a 131% increase in Q2 2025 (shares rose 54% over the following quarter), a 53% trim in Q1 2026 (shares rose 16% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2024 | 290.80K | $4.96M | New |
| Q2 2024 | 139.90K | $1.05M | Reduce |
| Q3 2024 | 131.79K | $622.07K | Reduce |
| Q4 2024 | 822.29K | $1.87M | Add |
| Q1 2025 | 458.97K | $635.68K | Reduce |
| Q2 2025 | 1.06M | $1.61M | Add |
| Q3 2025 | 1.54M | $3.61M | Add |
| Q4 2025 | 2.25M | $4.94M | Add |
| Q1 2026 | 1.07M | $2.87M | Reduce |
| Q2 2026 | 1.28M | $3.48M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CABA and 13F data
CABA (CABALETTA BIO INC) is a Health Care company. 37 other funds we track also report a position in CABA — the largest reported positions include Bain Capital Life Sciences Investors, LLC (US$53.6M), Cormorant Asset Management, LP (US$15.6M), Opaleye Management Inc. (US$12.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CABA
- Bain Capital Life Sciences Investors, LLC 17.24M sh · $53.62M · Q2 2026
- Cormorant Asset Management, LP 5.00M sh · $15.55M · Q2 2026
- Opaleye Management Inc. 3.86M sh · $12.02M · Q2 2026
- Stonepine Capital Management, LLC 917.10K sh · $2.85M · Q2 2026
- Blue Owl Capital Holdings LP 714.71K sh · $2.22M · Q2 2026
More on SUPERSTRING CAPITAL MANAGEMENT LP
FAQ
How long has SUPERSTRING CAPITAL MANAGEMENT LP held CABA?
SUPERSTRING CAPITAL MANAGEMENT LP has disclosed CABA holdings in 10 of the last 10 reported quarters, going back to Q1 2024.
What is SUPERSTRING CAPITAL MANAGEMENT LP's current position in CABA?
As of Q2 2026, SUPERSTRING CAPITAL MANAGEMENT LP holds 1.28M shares of CABA (CABALETTA BIO INC), valued at $3.48M, representing 2.20% of its reported portfolio and ranking #19.
Has SUPERSTRING CAPITAL MANAGEMENT LP been buying or selling CABA?
In the latest 13F filing (Q2 2026), SUPERSTRING CAPITAL MANAGEMENT LP increased its position in CABA.
Which other funds hold CABA?
Other major institutional holders of CABA include Bain Capital Life Sciences Investors, LLC, Cormorant Asset Management, LP, Opaleye Management Inc., among 37 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.